Hospitals in Morocco, Cameroon, and South Africa recently adopted its SOPHiA artificial intelligence offering, the firm's first crop of African customers.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
Omicia will use the proceeds to accelerate product development, expand sales and marketing, and extend variations of its flagship Opal Clinical platform for NGS data analysis.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
